Both methods were able to consistently detect differences in plasma NET levels between patient samples – healthy PMA-stimulated vs. unstimulated, SLE vs. healthy controls, and homozygous IRF5-SLE risk vs. non-risk. Here, IRF5 is linked to systemic lupus erythematosus.